Summary of Adicet's Conference Call Company Overview - **Company**: Adicet - **Industry**: Biotech, specifically focused on gamma delta CAR T cell therapies - **Key Executive**: Chen Schor, President and CEO Core Points and Arguments - **Leadership in CAR T Cell Therapies**: Adicet is positioned as a leader in gamma delta CAR T cell therapies, which are advantageous for treating autoimmune diseases and solid tumors due to their off-the-shelf availability and tissue penetration capabilities [3][4] - **Progress in Autoimmune Program**: The company is currently enrolling patients for seven different indications, with significant proof of concept data announced recently [4][6] - **Efficacy and Safety Data**: - In a recent study involving lupus nephritis (LN) and systemic lupus erythematosus (SLE), the safety profile was excellent, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed [6][7] - Efficacy results showed that out of five LN patients, three achieved complete renal response, and all patients reduced their steroid use significantly [7][8] - **Durability of Responses**: The data suggests promising durability of responses, with immune reset observed in patients, indicating long-term effectiveness of the therapy [11][12][14] - **Regulatory Plans**: Adicet plans to meet with the FDA in Q1 next year to discuss pivotal studies for LN and SLE, with expectations to start these studies in Q2 [23][24] Additional Important Information - **Enrollment and Interest**: The company has opened 25 centers for patient enrollment and is seeing robust interest, particularly in systemic sclerosis (SSC) and other autoimmune conditions [19][28] - **Manufacturing and Cost of Goods**: Adicet has a robust manufacturing process with a cost of goods sold (COGS) expected to be less than 10% of pricing, allowing for flexibility in pricing strategies [43][44] - **Financial Position**: As of September 30, Adicet has nearly $180 million in cash, which is projected to fund operations into the second half of 2027, covering multiple clinical updates and regulatory milestones [51] Conclusion Adicet is making significant strides in the field of gamma delta CAR T cell therapies, with promising safety and efficacy data in autoimmune diseases. The company is well-positioned for future growth with a solid financial foundation and strategic regulatory plans.